EUVIMEDEUVIMED entdecken
EditorialOpen Access

Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs

Ling Tang, Lijia Yuan, Ying Geng, Zhimin Yang iD, Guo Huang

Cancer Communications · 01.01.2026 · 46

DOI: 10.34133/cancomm.0032 ↗

Kurz gefasst

Editorial in der Zeitschrift Cancer Communications, online erschienen am 04.06.2026. Verfasst von Ling Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China.
  • National Medical Products Administration, Beijing, P. R. China.

ORCID-Profile: Zhimin Yang

Zitieren

APA

Tang, L., Yuan, L., Geng, Y., Yang, Z., & Huang, G. (2026). Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0032

Vancouver

Tang L, Yuan L, Geng Y, Yang Z, Huang G. Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs. Cancer Communications. 2026;46. doi:10.34133/cancomm.0032

BibTeX
@article{Tang2026,
  author = {Tang, Ling and Yuan, Lijia and Geng, Ying and Yang, Zhimin and Huang, Guo},
  title = {Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs},
  journal = {Cancer Communications},
  year = {2026},
  volume = {46},
  doi = {10.34133/cancomm.0032}
}
Kostenlos starten →